. Author manuscript; available in PMC: 2016 Jun 22.

Published in final edited form as: J Am Assoc Nurse Pract. 2014 Feb 10;26(12):681–688. doi: 10.1002/2327-6924.12109

Table 2.

Medications Prescribed for Participants (N = 150)

Medication	Total sample (N = 150) n (%)	Higher Quality (N = 75) n (%)	Lower Quality (N = 75) n (%)	p-value for group comparison^*
Methotrexate	101 (67.3)	50 (66.7)	51 (68.0)	0.9
Prednisone	61 (40.7)	33 (44.0)	28 (37.3)	0.4
Hydroxychloroquine	49 (32.7)	27 (36.0)	22 (29.3)	0.4
Etanercept	25 (16.7)	13 (17.3)	12 (16.0)	0.8
Adalimumab	34 (22.7)	20 (26.7)	14 (18.7)	0.2
Sulfasalazine	15 (10.0)	9 (12.0)	6 (8.0)	0.4
Leflunomide	12 (8.0)	9 (12.0)	3 (4.0)	0.07
Abatacept	10 (6.7)	4 (5.3)	6 (8.0)	0.5
Infliximab	6 (4.0)	3 (4.0)	3 (4.1)	>.9^a
Rituximab	4 (2.7)	0 (0.0)	4 (5.3)	0.1^a
Azathioprine	3 (2.0)	2 (2.7)	1 (1.3)	>.9^a
Certolizumab pegol	2 (1.3)	1 (1.3)	1 (1.3)	>.9^a

P-value labeled with ^a are based on Fisher’s exact test due to small expected cell counts; all others based on chi-squared test of association.